Evidence map›Paper›PMID 29142903›Full record

ArticleOncoscience2017

BETi induction of mitotic catastrophe: towing the LIN9.

Sylvia S Gayle, Jennifer M Sahni, Ruth A Keri

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Up to your NEK2 in CIN.Oncotarget · 2021
    Article
  2. The emerging role of BET inhibitors in breast cancer.Breast (Edinburgh, Scotland) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sylvia S GayleDepartment of Pharmacology, Case Western Reserve University, Cleveland, OH 44106, USA; Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH 44106, USA; Department of General Medical Sciences-Oncology, Case Western Reserve University, Cleveland, OH 44106, USA.
Jennifer M SahniDepartment of Pharmacology, Case Western Reserve University, Cleveland, OH 44106, USA; Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH 44106, USA; Department of General Medical Sciences-Oncology, Case Western Reserve University, Cleveland, OH 44106, USA.
Ruth A KeriDepartment of Pharmacology, Case Western Reserve University, Cleveland, OH 44106, USA; Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH 44106, USA; Department of General Medical Sciences-Oncology, Case Western Reserve University, Cleveland, OH 44106, USA.

Funding

RESEARCH ONCOLOGY TRAINING GRANTT32CA059366 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JACKSON, MARK W. · 1993 to 2025
$5.5M
Targeting BET proteins in Triple Negative Breast CancerR01CA206505 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI KERI, RUTH A. · 2016 to 2020
$1.8M
Identifying epigenetic drivers and their targets in aggressive breast and ovarian cancersF99CA212460 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI SAHNI, JENNIFER · 2016 to 2017
$68k
Epigenetically Reversing Paclitaxel Resistance in Triple Negative Breast CancersF32CA210426 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GAYLE, SYLVIA SHABAYA · 2017 to 2017
$62k
NCI NIH HHS F32 CA210426NCI NIH HHS F99 CA212460NCI NIH HHS R01 CA206505NCI NIH HHS T32 CA059366
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BET inhibitorbreast cancerLIN9mitotic catastropheoncogene

Identifiers

PMID29142903
PMCPMC5672896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.